The effects of freeze-dried Ganoderma lucidum mycelia on a recurrent oral ulceration rat model
Conventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum for the treatment of recurrent oral ulceration (ROU). Our aim of the present study was to evaluate whether freeze-dried powder from G. lucidum mycelia (FDPGLM) p...
Saved in:
Published in | BMC complementary and alternative medicine Vol. 17; no. 1; p. 511 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
01.12.2017
BioMed Central BMC |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Conventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum for the treatment of recurrent oral ulceration (ROU). Our aim of the present study was to evaluate whether freeze-dried powder from G. lucidum mycelia (FDPGLM) prevents ROU in rats.
A Sprague-Dawley (SD) rat model with ROU was established by autoantigen injection. The ROU rats were treated with three different dosages of FDPGLM and prednisone acetate (PA), and their effects were evaluated according to the clinical therapeutic evaluation indices of ROU.
High-dose FDPGLM induced significantly prolonged total intervals and a reduction in the number of ulcers and ulcer areas, thereby indicating that the treatment was effective in preventing ROU. Enzyme-linked immunosorbent assay (ELISA) showed that high-dose FDPGLM significantly enhanced the serum transforming growth factor-β1 (TGF-β1) levels, whereas reduced those of interleukin-6 (IL-6) and interleukin-17 (IL-17). Flow cytometry (FCM) showed that the proportion of CD4
CD25
Foxp3
(forkhead box P3) regulatory T cells (Tregs) significantly increased by 1.5-fold in the high-dose FDPGLM group compared to that in the rat model group (P < 0.01). The application of middle- and high-dose FDPGLM also resulted in the upregulation of Foxp3 and downregulation of retinoid-related orphan receptor gamma t(RORγt) mRNA.
High-dose FDPGLM possibly plays a role in ROU by promoting CD4
CD25
Foxp3
Treg and inhibiting T helper cell 17 differentiation. This study also shows that FDPGLM may be potentially used as a complementary and alternative medicine treatment scheme for ROU. |
---|---|
AbstractList | BACKGROUNDConventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum for the treatment of recurrent oral ulceration (ROU). Our aim of the present study was to evaluate whether freeze-dried powder from G. lucidum mycelia (FDPGLM) prevents ROU in rats.METHODSA Sprague-Dawley (SD) rat model with ROU was established by autoantigen injection. The ROU rats were treated with three different dosages of FDPGLM and prednisone acetate (PA), and their effects were evaluated according to the clinical therapeutic evaluation indices of ROU.RESULTSHigh-dose FDPGLM induced significantly prolonged total intervals and a reduction in the number of ulcers and ulcer areas, thereby indicating that the treatment was effective in preventing ROU. Enzyme-linked immunosorbent assay (ELISA) showed that high-dose FDPGLM significantly enhanced the serum transforming growth factor-β1 (TGF-β1) levels, whereas reduced those of interleukin-6 (IL-6) and interleukin-17 (IL-17). Flow cytometry (FCM) showed that the proportion of CD4+ CD25+ Foxp3+ (forkhead box P3) regulatory T cells (Tregs) significantly increased by 1.5-fold in the high-dose FDPGLM group compared to that in the rat model group (P < 0.01). The application of middle- and high-dose FDPGLM also resulted in the upregulation of Foxp3 and downregulation of retinoid-related orphan receptor gamma t(RORγt) mRNA.CONCLUSIONHigh-dose FDPGLM possibly plays a role in ROU by promoting CD4+ CD25+ Foxp3+ Treg and inhibiting T helper cell 17 differentiation. This study also shows that FDPGLM may be potentially used as a complementary and alternative medicine treatment scheme for ROU. Conventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum for the treatment of recurrent oral ulceration (ROU). Our aim of the present study was to evaluate whether freeze-dried powder from G. lucidum mycelia (FDPGLM) prevents ROU in rats. A Sprague-Dawley (SD) rat model with ROU was established by autoantigen injection. The ROU rats were treated with three different dosages of FDPGLM and prednisone acetate (PA), and their effects were evaluated according to the clinical therapeutic evaluation indices of ROU. High-dose FDPGLM induced significantly prolonged total intervals and a reduction in the number of ulcers and ulcer areas, thereby indicating that the treatment was effective in preventing ROU. Enzyme-linked immunosorbent assay (ELISA) showed that high-dose FDPGLM significantly enhanced the serum transforming growth factor-β1 (TGF-β1) levels, whereas reduced those of interleukin-6 (IL-6) and interleukin-17 (IL-17). Flow cytometry (FCM) showed that the proportion of CD4 CD25 Foxp3 (forkhead box P3) regulatory T cells (Tregs) significantly increased by 1.5-fold in the high-dose FDPGLM group compared to that in the rat model group (P < 0.01). The application of middle- and high-dose FDPGLM also resulted in the upregulation of Foxp3 and downregulation of retinoid-related orphan receptor gamma t(RORγt) mRNA. High-dose FDPGLM possibly plays a role in ROU by promoting CD4 CD25 Foxp3 Treg and inhibiting T helper cell 17 differentiation. This study also shows that FDPGLM may be potentially used as a complementary and alternative medicine treatment scheme for ROU. Background Conventional scientific studies had supported the use of polysaccharides and [beta]-glucans from a number of fungi, including Ganoderma lucidum for the treatment of recurrent oral ulceration (ROU). Our aim of the present study was to evaluate whether freeze-dried powder from G. lucidum mycelia (FDPGLM) prevents ROU in rats. Methods A Sprague-Dawley (SD) rat model with ROU was established by autoantigen injection. The ROU rats were treated with three different dosages of FDPGLM and prednisone acetate (PA), and their effects were evaluated according to the clinical therapeutic evaluation indices of ROU. Results High-dose FDPGLM induced significantly prolonged total intervals and a reduction in the number of ulcers and ulcer areas, thereby indicating that the treatment was effective in preventing ROU. Enzyme-linked immunosorbent assay (ELISA) showed that high-dose FDPGLM significantly enhanced the serum transforming growth factor-[beta]1 (TGF-[beta]1) levels, whereas reduced those of interleukin-6 (IL-6) and interleukin-17 (IL-17). Flow cytometry (FCM) showed that the proportion of CD4.sup.+ CD25.sup.+ Foxp3.sup.+ (forkhead box P3) regulatory T cells (Tregs) significantly increased by 1.5-fold in the high-dose FDPGLM group compared to that in the rat model group (P < 0.01). The application of middle- and high-dose FDPGLM also resulted in the upregulation of Foxp3 and downregulation of retinoid-related orphan receptor gamma t(ROR[gamma]t) mRNA. Conclusion High-dose FDPGLM possibly plays a role in ROU by promoting CD4.sup.+ CD25.sup.+ Foxp3.sup.+ Treg and inhibiting T helper cell 17 differentiation. This study also shows that FDPGLM may be potentially used as a complementary and alternative medicine treatment scheme for ROU. Keywords: Freeze-dried powder from Ganoderma lucidum mycelia, Rrecurrent oral ulcer, Rregulatory T cells, T-helper cells 17 Abstract Background Conventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum for the treatment of recurrent oral ulceration (ROU). Our aim of the present study was to evaluate whether freeze-dried powder from G. lucidum mycelia (FDPGLM) prevents ROU in rats. Methods A Sprague-Dawley (SD) rat model with ROU was established by autoantigen injection. The ROU rats were treated with three different dosages of FDPGLM and prednisone acetate (PA), and their effects were evaluated according to the clinical therapeutic evaluation indices of ROU. Results High-dose FDPGLM induced significantly prolonged total intervals and a reduction in the number of ulcers and ulcer areas, thereby indicating that the treatment was effective in preventing ROU. Enzyme-linked immunosorbent assay (ELISA) showed that high-dose FDPGLM significantly enhanced the serum transforming growth factor-β1 (TGF-β1) levels, whereas reduced those of interleukin-6 (IL-6) and interleukin-17 (IL-17). Flow cytometry (FCM) showed that the proportion of CD4+ CD25+ Foxp3+ (forkhead box P3) regulatory T cells (Tregs) significantly increased by 1.5-fold in the high-dose FDPGLM group compared to that in the rat model group (P < 0.01). The application of middle- and high-dose FDPGLM also resulted in the upregulation of Foxp3 and downregulation of retinoid-related orphan receptor gamma t(RORγt) mRNA. Conclusion High-dose FDPGLM possibly plays a role in ROU by promoting CD4+ CD25+ Foxp3+ Treg and inhibiting T helper cell 17 differentiation. This study also shows that FDPGLM may be potentially used as a complementary and alternative medicine treatment scheme for ROU. Conventional scientific studies had supported the use of polysaccharides and [beta]-glucans from a number of fungi, including Ganoderma lucidum for the treatment of recurrent oral ulceration (ROU). Our aim of the present study was to evaluate whether freeze-dried powder from G. lucidum mycelia (FDPGLM) prevents ROU in rats. A Sprague-Dawley (SD) rat model with ROU was established by autoantigen injection. The ROU rats were treated with three different dosages of FDPGLM and prednisone acetate (PA), and their effects were evaluated according to the clinical therapeutic evaluation indices of ROU. High-dose FDPGLM induced significantly prolonged total intervals and a reduction in the number of ulcers and ulcer areas, thereby indicating that the treatment was effective in preventing ROU. Enzyme-linked immunosorbent assay (ELISA) showed that high-dose FDPGLM significantly enhanced the serum transforming growth factor-[beta]1 (TGF-[beta]1) levels, whereas reduced those of interleukin-6 (IL-6) and interleukin-17 (IL-17). Flow cytometry (FCM) showed that the proportion of CD4.sup.+ CD25.sup.+ Foxp3.sup.+ (forkhead box P3) regulatory T cells (Tregs) significantly increased by 1.5-fold in the high-dose FDPGLM group compared to that in the rat model group (P < 0.01). The application of middle- and high-dose FDPGLM also resulted in the upregulation of Foxp3 and downregulation of retinoid-related orphan receptor gamma t(ROR[gamma]t) mRNA. High-dose FDPGLM possibly plays a role in ROU by promoting CD4.sup.+ CD25.sup.+ Foxp3.sup.+ Treg and inhibiting T helper cell 17 differentiation. This study also shows that FDPGLM may be potentially used as a complementary and alternative medicine treatment scheme for ROU. |
ArticleNumber | 511 |
Audience | Academic |
Author | Zhong, Xiaohong Liu, Dongbo Xie, Ling Xia, Zhilan Liu, Lin |
Author_xml | – sequence: 1 givenname: Ling surname: Xie fullname: Xie, Ling organization: Hunan Engineering Research Center of Edible Fungi, Changsha, China – sequence: 2 givenname: Xiaohong surname: Zhong fullname: Zhong, Xiaohong organization: College of Horticulture and Landscape Architecture, Hunan Agricultural University, Changsha, China – sequence: 3 givenname: Dongbo surname: Liu fullname: Liu, Dongbo organization: State Key Laboratory of Subhealth Intervention Technology, Changsha, China – sequence: 4 givenname: Lin surname: Liu fullname: Liu, Lin organization: The First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, China – sequence: 5 givenname: Zhilan orcidid: 0000-0002-6628-9009 surname: Xia fullname: Xia, Zhilan email: 27991288@qq.com, 27991288@qq.com organization: Hunan Engineering Research Center of Edible Fungi, Changsha, China. 27991288@qq.com |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29191190$$D View this record in MEDLINE/PubMed |
BookMark | eNptkt1r1TAYxotM3If-Ad5IQBBvOvOmzdeNMIbOwcCbeWtI0zfnZLTNTNrB_OtNPXOcAxJIQvJ7nuRNntPqaIoTVtVboOcASnzKwDQVNQVZM8qgVi-qE2glq4VS7Ghvflyd5nxHC6igfVUdMw0aQNOT6uftFgl6j27OJHriE-JvrPsUsCdXdoo9ptGSYXGhX0YyPjocgiVxIpYkdEtKOM0kJjuQZXCY7BzKXhnIWKTD6-qlt0PGN0_jWfXj65fby2_1zfer68uLm9px0cw1Fx46ITvrRK8lQ-BoObXQ2Ea26KnmknfKIrMOlHSysbqTXFAlaM85-Oasut759tHemfsURpseTbTB_F2IaWNsmoMb0PSofMvKGUq0rQOmpBbQKd7oFrtGuuL1eed1v3Qj9q4UWMo7MD3cmcLWbOKD4ZJqrXQx-PhkkOKvBfNsxpDLuw12wrhkA1qCaEvPCvp-h25suVqYfCyObsXNBW9Fs2KqUOf_oUrrcQyuZMKHsn4g-LAn2KId5m2Ow7J-Tj4EYQe6FHNO6J_LBGrWjJldxkyJjlkzZlbNu_33eVb8C1XzB8mizJE |
CitedBy_id | crossref_primary_10_1159_000536226 crossref_primary_10_1016_j_archoralbio_2023_105828 crossref_primary_10_1016_j_lwt_2020_109494 |
Cites_doi | 10.1007/s10753-015-0229-7 10.1177/1534735414568721 10.1248/bpb.b13-01006 10.1016/j.phytochem.2014.10.019 10.1084/jem.20040165 10.1097/MIB.0000000000000439 10.1089/acm.2008.0118 10.4049/jimmunol.173.2.755 10.1016/j.fbp.2009.07.002 10.4049/jimmunol.0901881 10.1007/s10719-013-9479-5 10.1016/j.jaut.2009.03.008 10.1038/nature07021 10.1590/S0102-86502011000300012 10.1093/jmcb/mjr033 10.1146/annurev.immunol.21.120601.141122 10.2174/1872213X08666140619110657 10.1007/s13213-013-0723-9 10.1021/bp010136g 10.1016/j.yjmcc.2006.01.008 10.1089/jmf.2004.7.417 10.1254/jphs.13209FP 10.1111/j.1600-0714.1994.tb01108.x 10.1667/RR1013.1 10.1002/bit.25288 10.1371/journal.pone.0049008 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2017 BioMed Central Ltd. The Author(s). 2017 |
Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: The Author(s). 2017 |
DBID | NPM AAYXX CITATION 7X8 5PM DOA |
DOI | 10.1186/s12906-017-2021-8 |
DatabaseName | PubMed CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | PubMed CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1472-6882 |
EndPage | 511 |
ExternalDocumentID | oai_doaj_org_article_de8f422e18644c1287961b85394eb37c A546364198 10_1186_s12906_017_2021_8 29191190 |
Genre | Journal Article |
GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 6PF A8Z AAFWJ AAHBH AAWTL ACGFO ACGFS ACMJI ACPRK ADBBV ADINQ ADRAZ AENEX AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AOIJS BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C24 CS3 DIK DU5 E3Z EBD EBS EJD EMB EMOBN ESTFP F5P GROUPED_DOAJ GX1 H13 HYE IAO IHR IHW INH INR ITC KQ8 M48 M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PQQKQ PROAC RBZ RNS ROL RPM RSV SMD SV3 TR2 UNMZH W2D WOQ WOW XSB AAYXX CITATION AFGXO 7X8 5PM |
ID | FETCH-LOGICAL-c563t-56f1b67bac6d972e15ea50a13a374ef09575b8ae2ac187c73a9b7560860d551f3 |
IEDL.DBID | RPM |
ISSN | 1472-6882 |
IngestDate | Thu Sep 05 15:44:52 EDT 2024 Tue Sep 17 21:26:53 EDT 2024 Sun Sep 29 07:34:12 EDT 2024 Thu Feb 22 23:30:39 EST 2024 Wed Jan 10 04:20:42 EST 2024 Tue Aug 20 22:12:34 EDT 2024 Thu Sep 12 18:33:20 EDT 2024 Sat Sep 28 08:49:09 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Issue | 1 |
Keywords | T-helper cells 17 Rrecurrent oral ulcer Freeze-dried powder from Ganoderma lucidum mycelia Rregulatory T cells |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c563t-56f1b67bac6d972e15ea50a13a374ef09575b8ae2ac187c73a9b7560860d551f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-6628-9009 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709989/ |
PMID | 29191190 |
PQID | 1971641972 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_de8f422e18644c1287961b85394eb37c pubmedcentral_primary_oai_pubmedcentral_nih_gov_5709989 proquest_miscellaneous_1971641972 gale_infotracmisc_A546364198 gale_infotracacademiconefile_A546364198 gale_healthsolutions_A546364198 crossref_primary_10_1186_s12906_017_2021_8 pubmed_primary_29191190 |
PublicationCentury | 2000 |
PublicationDate | 2017-Dec-01 2017-12-1 20171201 2017-12-01 |
PublicationDateYYYYMMDD | 2017-12-01 |
PublicationDate_xml | – month: 12 year: 2017 text: 2017-Dec-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC complementary and alternative medicine |
PublicationTitleAlternate | BMC Complement Altern Med |
PublicationYear | 2017 |
Publisher | BioMed Central Ltd BioMed Central BMC |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
References | JM Fletcher (2021_CR30) 2009; 183 XM Yang (2021_CR15) 2012; 37 Y Gao (2021_CR4) 2004; 7 MA Hasnat (2021_CR9) 2015; 114 Y Xu (2021_CR13) 2014; 111 Y Fujisawa (2021_CR27) 2011; 29 A Chatterjee (2021_CR11) 2013; 30 L Zhang (2021_CR18) 2016; 1 X HHZL (2021_CR17) 2013; 11 A Sun (2021_CR1) 1994; 23 GM Cavalcante (2021_CR21) 2011; 26 DQ Tran (2021_CR31) 2012; 4 S SB (2021_CR22) 2004; 173 DT Altaei (2021_CR2) 2012; 25 S Sakaguchi (2021_CR28) 2004; 22 S Yang (2021_CR32) 2006; 40 MR Ehrenstein (2021_CR29) 2004; 200 JMJY Zheng (2021_CR16) 2010; 11 S Hata (2021_CR19) 2014; 124 QH Fang (2021_CR5) 2002; 18 S Cheng (2021_CR8) 2015; 14 N Bhardwaj (2021_CR7) 2014; 8 C Liu (2021_CR10) 2015; 21 R Askin (2021_CR6) 2010; 88 T Nakashima (2021_CR20) 2014; 37 MF Moraes-Fontes (2021_CR23) 2009; 33 M Koray (2021_CR12) 2009; 15 M Upadhyay (2021_CR14) 2014; 64 2021_CR3 L Yang (2021_CR26) 2008; 454 U Kaufmann (2021_CR25) 2012; 7 F Tago (2021_CR24) 2008; 169 |
References_xml | – volume: 1 start-page: 113 year: 2016 ident: 2021_CR18 publication-title: Inflammation doi: 10.1007/s10753-015-0229-7 contributor: fullname: L Zhang – volume: 14 start-page: 249 year: 2015 ident: 2021_CR8 publication-title: Integr Cancer Ther doi: 10.1177/1534735414568721 contributor: fullname: S Cheng – volume: 37 start-page: 671 year: 2014 ident: 2021_CR20 publication-title: Biol Pharm Bull doi: 10.1248/bpb.b13-01006 contributor: fullname: T Nakashima – volume: 114 start-page: 125 year: 2015 ident: 2021_CR9 publication-title: Phytochemistry doi: 10.1016/j.phytochem.2014.10.019 contributor: fullname: MA Hasnat – volume: 200 start-page: 277 year: 2004 ident: 2021_CR29 publication-title: J Exp Med doi: 10.1084/jem.20040165 contributor: fullname: MR Ehrenstein – volume: 21 start-page: 1918 year: 2015 ident: 2021_CR10 publication-title: Inflamm Bowel Dis doi: 10.1097/MIB.0000000000000439 contributor: fullname: C Liu – volume: 15 start-page: 111 year: 2009 ident: 2021_CR12 publication-title: J Altern Complement Med doi: 10.1089/acm.2008.0118 contributor: fullname: M Koray – volume: 173 start-page: 755 year: 2004 ident: 2021_CR22 publication-title: J Immunol doi: 10.4049/jimmunol.173.2.755 contributor: fullname: S SB – volume: 88 start-page: 291 year: 2010 ident: 2021_CR6 publication-title: Food Bioprod Process doi: 10.1016/j.fbp.2009.07.002 contributor: fullname: R Askin – volume: 183 start-page: 7602 year: 2009 ident: 2021_CR30 publication-title: J Immunol doi: 10.4049/jimmunol.0901881 contributor: fullname: JM Fletcher – volume: 30 start-page: 759 issue: 8 year: 2013 ident: 2021_CR11 publication-title: Glycoconj J doi: 10.1007/s10719-013-9479-5 contributor: fullname: A Chatterjee – volume: 33 start-page: 109 year: 2009 ident: 2021_CR23 publication-title: J Autoimmun doi: 10.1016/j.jaut.2009.03.008 contributor: fullname: MF Moraes-Fontes – volume: 454 start-page: 350 year: 2008 ident: 2021_CR26 publication-title: Nature doi: 10.1038/nature07021 contributor: fullname: L Yang – volume: 29 start-page: 86 year: 2011 ident: 2021_CR27 publication-title: Asian Pac J Allergy Immunol contributor: fullname: Y Fujisawa – volume: 26 start-page: 227 year: 2011 ident: 2021_CR21 publication-title: Acta Cir Bras doi: 10.1590/S0102-86502011000300012 contributor: fullname: GM Cavalcante – ident: 2021_CR3 – volume: 37 start-page: 2612 year: 2012 ident: 2021_CR15 publication-title: Zhongguo Zhong Yao Za Zhi contributor: fullname: XM Yang – volume: 11 start-page: 21463 year: 2013 ident: 2021_CR17 publication-title: Int J Mol Sci contributor: fullname: X HHZL – volume: 4 start-page: 29 year: 2012 ident: 2021_CR31 publication-title: J Mol Cell Biol doi: 10.1093/jmcb/mjr033 contributor: fullname: DQ Tran – volume: 22 start-page: 531 year: 2004 ident: 2021_CR28 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.21.120601.141122 contributor: fullname: S Sakaguchi – volume: 8 start-page: 104 year: 2014 ident: 2021_CR7 publication-title: Recent Patents Inflamm Allergy Drug Discov doi: 10.2174/1872213X08666140619110657 contributor: fullname: N Bhardwaj – volume: 64 start-page: 839 year: 2014 ident: 2021_CR14 publication-title: Ann Microbiol doi: 10.1007/s13213-013-0723-9 contributor: fullname: M Upadhyay – volume: 18 start-page: 51 year: 2002 ident: 2021_CR5 publication-title: Biotechnol Prog doi: 10.1021/bp010136g contributor: fullname: QH Fang – volume: 40 start-page: 570 issue: 4 year: 2006 ident: 2021_CR32 publication-title: J Mol Cell Cardiol doi: 10.1016/j.yjmcc.2006.01.008 contributor: fullname: S Yang – volume: 7 start-page: 417 issue: 4 year: 2004 ident: 2021_CR4 publication-title: J Med Food doi: 10.1089/jmf.2004.7.417 contributor: fullname: Y Gao – volume: 11 start-page: 1251 year: 2010 ident: 2021_CR16 publication-title: Clin Rheumatol contributor: fullname: JMJY Zheng – volume: 124 start-page: 230 year: 2014 ident: 2021_CR19 publication-title: J Pharmacol Sci doi: 10.1254/jphs.13209FP contributor: fullname: S Hata – volume: 23 start-page: 172 year: 1994 ident: 2021_CR1 publication-title: J Oral Pathol Med doi: 10.1111/j.1600-0714.1994.tb01108.x contributor: fullname: A Sun – volume: 169 start-page: 59 year: 2008 ident: 2021_CR24 publication-title: Radiat Res doi: 10.1667/RR1013.1 contributor: fullname: F Tago – volume: 25 start-page: 39 issue: 1 year: 2012 ident: 2021_CR2 publication-title: Am J Dent contributor: fullname: DT Altaei – volume: 111 start-page: 2358 year: 2014 ident: 2021_CR13 publication-title: Biotechnol Bioeng doi: 10.1002/bit.25288 contributor: fullname: Y Xu – volume: 7 start-page: e49008 year: 2012 ident: 2021_CR25 publication-title: PLoS One doi: 10.1371/journal.pone.0049008 contributor: fullname: U Kaufmann |
SSID | ssj0017814 |
Score | 1.8310089 |
Snippet | Conventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum for the treatment of... Background Conventional scientific studies had supported the use of polysaccharides and [beta]-glucans from a number of fungi, including Ganoderma lucidum for... Conventional scientific studies had supported the use of polysaccharides and [beta]-glucans from a number of fungi, including Ganoderma lucidum for the... BACKGROUNDConventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum for the... Abstract Background Conventional scientific studies had supported the use of polysaccharides and β-glucans from a number of fungi, including Ganoderma lucidum... |
SourceID | doaj pubmedcentral proquest gale crossref pubmed |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 511 |
SubjectTerms | Alternative medicine Autoimmunity Bone morphogenetic proteins Enzyme-linked immunosorbent assay Freeze-dried powder from Ganoderma lucidum mycelia Glucocorticoids Health aspects Interleukins Polysaccharides Prednisone Recurrence (Disease) Rrecurrent oral ulcer Rregulatory T cells T cells T-helper cells 17 Transforming growth factors |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Li9RAEG5kD-JFfBtdtQVBEMKm0-_jKq6LsJ5c2JNNv4IDM5lldnJwf_1WdTLDBA9ePAXSFZKuR1dVuvorQj4EboU0MdU6t74WQdnaJJ7rxnvRZW84KzizFz_U-aX4fiWvDlp9YU3YCA88Mu4kZdOJts3MgOeOsJpqq1gAJ2MF5IE6ltWXyV0yNe0fIJDTtIcJD57c4N8WzJw1aEXLajPzQgWs_-8l-cAnzeslDxzQ2SPycIoc6en4xY_Jvdw_Ifcvpr3xp-QXSJxO5Rl03dFuk_NtrhPkwol-8z02PVt5uhziIg0ruvoT83Lh6bqnnm7wrzviNFE8sE-HZcyjZlC40NIt5xm5PPv688t5PXVPqKNUfFtL1bGgdPBRJauBgTJ72XjGPdcidxBaaRmMBxFFZnTU3NugIf4xqkkQRnX8OTnq131-SSjLLU8RZIro-01QwRttRJZtx3hIsanIpx033fUIkuFKcmGUG1nvgPUOWe9MRT4jv_eEiG9dboDU3SR19y-pV-QdSsuNh0X3VupOEd1fCWbhNR8LBdopCC366bgBzAgRr2aUxzNKsK84G36_0wiHQ1iU1uf1cOMYwm8J7NtWkRejhuxn1VpIhCHYqoie6c5s2vORfvG7wHtLDVG7sa_-B59ekwctan2pvzkmR9vNkN9AFLUNb4vB3AHmPBfF priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9QwFA7rCuKLeLe6agRBEKpNkybpg8gqroswPjmwT4bcqgMzrXZmwPXXe07aGbe4jz4VmlPanEvznVy-Q8hzx2tRaR9yFUubCyfrXAce88Ja0USrOUs8s7PP8nQuPp1VZwdkV95qVOD60tQO60nN--WrXz_P30LAv0kBr-XrNc6lYF6swOYly_UVcrUUXKDDz8TfRQVkdxoXNi99bDI0JQb_f__TFwaq6SbKC6PSyU1yY4ST9Hiw_y1yENvb5NpsXDC_Q76CG9BxzwbtGtr0Mf6OeYAEOdCPtsVKaCtLl1u_CNsVXZ37uFxY2rXU0h6n4pG8ieIpfrpd-ji4C4ULTSV07pL5yYcv70_zsaRC7ivJN3klG-akctbLUKsysiraqrCMW65EbABvqcppC3bzTCuvuK2dAlCkZREAWzX8HjlsuzY-IJTFkgcPhkZK_sJJZ7XSIlZlw7gLvsjIy502zY-BOcOkjENLM6jegOoNqt7ojLxDfe8FkfQ63ej6b2aMIROibkQJH60BxHkYWFUtmQO8UYvouPIZeYrWMsMJ0n3ommOk_JeC1fCaF0kC3QmM5u14BgF6hDRYE8mjiSQEnZ80P9t5hMEm3KnWxm67Ngw5uQQWc8vI_cFD9r0qa8iOAYFlRE18Z9LtaUu7-J44vysFUF7XD_-Hnh6R6yV6fdqUc0QON_02PgZotXFPUsD8AVHjH7Q priority: 102 providerName: Scholars Portal |
Title | The effects of freeze-dried Ganoderma lucidum mycelia on a recurrent oral ulceration rat model |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29191190 https://search.proquest.com/docview/1971641972 https://pubmed.ncbi.nlm.nih.gov/PMC5709989 https://doaj.org/article/de8f422e18644c1287961b85394eb37c |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEBVJDqWX0u-6TVMVCoWCsytLluRjEpqGwpZSGgg9VEiynC6s7bBZH5Jf3xnZXtb01osNlowtvydrRhq9IeSD44XItS9TFTKbCieLVJc8pHNrRRWs5izqzC6-yYtL8fUqv9oj-bgXJgbte7c8blb1cbP8E2Mrb2o_G-PEZt8XZ7kCu0YXs32yrzgfXfRh6QA1nIblS6bl7BYnWtBpVkCIjKWYoC8rwEth-BveGYuiZP-_P-adkWkaNbkzDJ0_Jo8G-5Ge9O_5hOyF5il5sBhWyJ-R34A7HYI0aFvRah3CfUhL8IhL-sU2mPqstnTV-WXZ1bS-82G1tLRtqKVrnHtHtSaK2_Zpt_Kh5weFE405c56Ty_PPP88u0iGHQupzyTdpLivmpHLWy7JQWWB5sPncMm65EqECA0vlTlsAyjOtvOK2cAqsIC3nJRhTFX9BDpq2Ca8IZSHjpQdkUYN_7qSzWmkR8qxi3JV-npBP49c0N71UhokuhpamR8EACgZRMDohp_i9txVR5TpeaNfXZsDalEFXIoOX1mC1eRhJVSGZAwOjEMFx5RPyDtEy_ZbRbV81J6jxLwUr4DEfYw3srQCat8OmA2gR6l5Nah5OakIv85Pi9yMjDBZhaFoT2u7WMBThEpi9LSEve4ZsWzUSLSFqwp1Js6clwPko8j1w_PV_3_mGPMyQ9TH05pAcbNZdeAsG1MYdxYkHOC6EhuOP019HsQv9BUFcHB4 |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27957,27958,53827,53829 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwELbGkIAXfg8CgxkJCQkpbR0ntvM4JkaBdeJhQ3vCsh0HKpp06poH9tdz5yRVA0_wFCm-KLncZ_vOPn9HyGvL8zRTroilT0ycWpHHquA-nhiTlt4ozgLP7OxUTM_TTxfZxQ7J-rMwIWnf2fmoXlSjev4j5FZeVm7c54mNv8yOMgl-jcrHN8hN6K-J7IP0bvMAWZy6DUymxPgKl1owbJYAiYTFWKIvySFOYTgQb81GgbT_76F5a24a5k1uTUTH98jXXoU2_-TnqFnbkbv-g93xn3W8T-52rik9bJsfkB1fPyS3Zt3m-yPyDSBFu_wPuixpufL-2scFBNsF_WBqrKpWGbpo3LxoKlr9cn4xN3RZU0NXuKyPRFAUGQFos3C-hR6FCw3leB6T8-P3Z0fTuCvPELtM8HWciZJZIa1xoshl4lnmTTYxjBsuU1-C7yYzqwxgwDElneQmtxIcLCUmBfhpJd8ju_Wy9k8JZT7hhQPQIL3_xAprlFSpz5KScVu4SUTe9mbSly0Lhw7RixK6Na8G82o0r1YReYeG3AgigXa4sVx9190v1oVXZZrARytwCB1M0jIXzILvkqfecukicoAw0O1p1M0woA-xfIBIWQ6veRMkcCAANDjTnWcAjZBSayC5P5CEDuwGza96qGlswqy32i-bK82Q3yvFwnARedJCb6NVj-CIyAEoB2oPWwBqgT-8g9az_37ygNyens1O9MnH08_PyZ0Eu1bI8Nknu-tV41-An7a2L0Ov_A3NhjtH |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZgkVZceD8KC2skJCSktHWc2M5xWSjLo6s9sNKKA5ZfgYo2rbrNgf31zDhJ1cBtT5HiiZLJfLZn7PE3hLy2vMhy5XwiQ2qSzIoiUZ6HZGxMVgajOIs8s9NTcXKefb7IL3ZKfcWkfWdnw2q-GFazXzG3crVwoy5PbHQ2Pc4l-DWqGK18ObpJbkGfTYsuUG83EJDJqd3EZEqMLnG5BUNnCbBIWYJl-tICYhWGg_HOjBSJ-_8fnnfmp37u5M5kNLlLvndqNDkov4f1xg7d1T8Mj9fS8x6507qo9KgRuU9uhOoB2Z-2m_APyQ-AFm3zQOiypOU6hKuQeAi6Pf1oKqyutjB0XruZrxd08ceF-czQZUUNXePyPhJCUWQGoPXchQaCFC40luV5RM4nH74dnyRtmYbE5YJvklyUzAppjRO-kGlgeTD52DBuuMxCCT6czK0ygAXHlHSSm8JKcLSUGHvw10r-mOxVyyo8JZSFlHsH4EGa_7EV1iipspCnJePWu_GAvO1MpVcNG4eOUYwSujGxBhNrNLFWA_IOjbkVRCLteGO5_qnb36x9UGWWwkcrcAwdTNayEMyCD1NkwXLpBuQQoaCbU6nb4UAfYRkBkbECXvMmSuCAAIhwpj3XABohtVZP8qAnCR3Z9ZpfdXDT2ITZb1VY1peaIc9XhgXiBuRJA7-tVh2KB0T2gNlTu98CcIs84i28nl37yUOyf_Z-or9-Ov3ynNxOsXfFRJ8DsrdZ1-EFuGsb-zJ2zL-sUj3H |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+effects+of+freeze-dried+Ganoderma+lucidum+mycelia+on+a+recurrent+oral+ulceration+rat+model&rft.jtitle=BMC+complementary+and+alternative+medicine&rft.au=Ling+Xie&rft.au=Xiaohong+Zhong&rft.au=Dongbo+Liu&rft.au=Lin+Liu&rft.date=2017-12-01&rft.pub=BMC&rft.eissn=1472-6882&rft.volume=17&rft.issue=1&rft.spage=1&rft.epage=11&rft_id=info:doi/10.1186%2Fs12906-017-2021-8&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_de8f422e18644c1287961b85394eb37c |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1472-6882&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1472-6882&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1472-6882&client=summon |